[go: up one dir, main page]

WO2009008496A1 - Anti-hsulf1 antibody - Google Patents

Anti-hsulf1 antibody Download PDF

Info

Publication number
WO2009008496A1
WO2009008496A1 PCT/JP2008/062547 JP2008062547W WO2009008496A1 WO 2009008496 A1 WO2009008496 A1 WO 2009008496A1 JP 2008062547 W JP2008062547 W JP 2008062547W WO 2009008496 A1 WO2009008496 A1 WO 2009008496A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cell
hsulf1
atrl
ferm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/062547
Other languages
French (fr)
Japanese (ja)
Inventor
Yasuyuki Kaneta
Mitsuru Ono
Toshinori Agatsuma
Keisuke Fukuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of WO2009008496A1 publication Critical patent/WO2009008496A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

[PROBLEMS] To provide an antibody or the like which is capable of inhibiting the canceration of a cell and/or the cell proliferation of a tumor cell. [MEANS FOR SOLVING PROBLEMS] Disclosed are: an antibody which can bind to HSulf1 specifically and can inhibit the cell proliferation of a cell expressing the protein; an antibody which can bind to an epitope that can be bound through an antibody produced by a mouse hybridoma DS-ATRL-87A3 (FERM BP-10835); an antibody comprising a complementarity determining region of an antibody produced by a mouse hybridoma DS-ATRL-87A3 (FERM BP-10835); others; and a pharmaceutical agent comprising any one ofthese antibodies.
PCT/JP2008/062547 2007-07-12 2008-07-11 Anti-hsulf1 antibody Ceased WO2009008496A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007182882 2007-07-12
JP2007-182882 2007-07-12

Publications (1)

Publication Number Publication Date
WO2009008496A1 true WO2009008496A1 (en) 2009-01-15

Family

ID=40228666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/062547 Ceased WO2009008496A1 (en) 2007-07-12 2008-07-11 Anti-hsulf1 antibody

Country Status (2)

Country Link
TW (1) TW200914044A (en)
WO (1) WO2009008496A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2570813A4 (en) * 2010-05-13 2013-12-11 Consejo Superior Investigacion METHOD FOR THE DIAGNOSIS / PROGNOSIS OF DARM CANCER
JPWO2018207931A1 (en) * 2017-05-12 2020-03-19 三井化学株式会社 Recombinant microorganism, method for producing pyridoxamine or salt thereof using recombinant microorganism, and method for producing pyridoxal or salt thereof using recombinant microorganism

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025170738A1 (en) * 2024-02-05 2025-08-14 Ccbiotech Inc. Anti-sulfatase-related antigen specific antibody, detection kit comprising anti-sulfatase-related antigen specific antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005079390A2 (en) * 2004-02-13 2005-09-01 Boston Biomedical Research Institute Inhibition of fgf signaling
US20060063230A1 (en) * 2000-12-27 2006-03-23 Roman Naworth Sulfatases and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063230A1 (en) * 2000-12-27 2006-03-23 Roman Naworth Sulfatases and methods of use thereof
WO2005079390A2 (en) * 2004-02-13 2005-09-01 Boston Biomedical Research Institute Inhibition of fgf signaling

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AI X. ET AL.: "QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling", THE JOURNAL OF CELL BIOLOGY, vol. 162, no. 2, 2003, pages 341 - 351 *
MORIMOTO-TOMITA M. ET AL.: "Novel extracellular sulfatases: potential roles in cancer", TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY, vol. 15, no. 83, May 2003 (2003-05-01), pages 159 - 164 *
NARITA K. ET AL.: "HSulf-1 inhibits angiogenesis and tumorigenesis in vivo", CANCER RESEARCH, vol. 66, no. 12, 2006, pages 6025 - 6032 *
NARITA K. ET AL.: "Loss of HSulf1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, no. 19, May 2007 (2007-05-01), pages 14413 - 14420 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2570813A4 (en) * 2010-05-13 2013-12-11 Consejo Superior Investigacion METHOD FOR THE DIAGNOSIS / PROGNOSIS OF DARM CANCER
JPWO2018207931A1 (en) * 2017-05-12 2020-03-19 三井化学株式会社 Recombinant microorganism, method for producing pyridoxamine or salt thereof using recombinant microorganism, and method for producing pyridoxal or salt thereof using recombinant microorganism

Also Published As

Publication number Publication date
TW200914044A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
WO2009071696A3 (en) Humanized antibody molecules specific for il-31
EP2152754B8 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
IL197928A (en) Humanized monoclonal antibody that binds to steap-1, immunoconjugates and uses thereof
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
WO2007109376A3 (en) Anti-tumor cell antigen antibody therapeutics
WO2009028639A1 (en) Anti-epha2 antibody
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
UA94628C2 (en) Humanized monoclonal antibody that binds to steap-1 and use thereof
MX343624B (en) Antibodies to receptor of advanced glycation end products (rage) and uses thereof.
WO2008022295A3 (en) Prlr-specific antibody and uses thereof
CL2007003479A1 (en) Human anti-cd22 monoclonal antibody or an antigen-binding fragment thereof; nucleic acid, vector, host cell; Preparation method; composition; immunoconjugate; and its use to inhibit the growth of a tumor or treat an inflammatory or autoimmune disorder in a subject.
WO2006084264A3 (en) Cd20 antibody variants and uses thereof
NZ604007A (en) Monoclonal antibodies against her2 epitope
WO2005103081A3 (en) Human monoclonal antibodies against cd20
IL212633A (en) Monoclonal antibody or antigen-binding fragment thereof, pharmaceutical compositions comprising the same and use thereof for the manufacture of medicaments for the treatment of cancer
MX2013006428A (en) Tnf-a binding proteins.
WO2012156532A8 (en) Anti-human-her3 antibodies and uses thereof
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
WO2010073012A3 (en) Human anti tshr antibodies
EP2487189B8 (en) Monoclonal antibodies against gt468 for treatment of cancer
EP1998807A4 (en) Methods for humanizing antibodies and humanized antibodies made thereby
IL220622A0 (en) Monoclonal antibodies against activated and unactivated protein c
WO2012082752A3 (en) Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791077

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08791077

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP